Sheets Smith Investment Management’s NovoCure NVCR Stock Holding History

Sheets Smith Investment Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$1.14M	Buy	+6,575	New	+$900K	1.03%	31

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sheets Smith Investment Management's NVCR Position: Q4 2020 in Review

Sheets Smith Investment Management opened a new position in NovoCure (NVCR) in Q4 2020: 6,575 shares worth $1.14M. The stake represents 1.03% of the portfolio and ranks #31 among its holdings.

356 funds tracked by Wall St. Rank hold NVCR as of Q4 2020.

Sheets Smith Investment Management held 6,575 shares of NovoCure worth $1.14M as of Q4 2020.
NovoCure was a new Sheets Smith Investment Management position in Q4 2020.
NovoCure made up 1.03% of Sheets Smith Investment Management's portfolio in Q4 2020, its #31 holding.
356 funds tracked by Wall St. Rank held NovoCure as of Q4 2020.

Based on Sheets Smith Investment Management's 13F filing for Q4 2020, filed 24 Feb 2021.